In the new role, Schellhorn will guide Monteris’ continuing development and commercialization of NeuroBlate System, a proprietary MRI-guided, focused ablation device for the treatment of brain tumors.

Monteris Medical president and CEO said: "I am delighted to be joining the Monteris team as we broaden the availability of this new, minimally invasive treatment for patients suffering from both primary and metastatic brain tumors."

Previously, Schellhorn worked at Barrx Medical, a provider of treatment for Barrett’s Esophagus, as chief commercialization officer.

Schellhorn served as president and CEO of Softscope Medical Technologies and as vice president of sales and marketing for the Peripheral Vascular Division of ev3.

Schellhorn also served as vice president and general manager of ACMI Corporation (acquired by Gyrus PLC in 2005), along with various management positions within Boston Scientific.